Today: 7 February 2026
Subscribe
Browse Category

Fintech News 31 December 2025 - 8 January 2026

Mastercard stock climbs as Apple taps JPMorgan for Apple Card, keeps Mastercard network

Mastercard stock climbs as Apple taps JPMorgan for Apple Card, keeps Mastercard network

New York, Jan 8, 2026, 12:43 EST — Regular session Mastercard Incorporated shares rose on Thursday after Apple said JPMorgan Chase will become the new issuer of the Apple Card while Mastercard remains the payment network. Mastercard stock was up about 0.8% at $584.47 in midday trading. Reuters The Apple Card is a rare, high-profile co-brand in U.S. consumer finance, and networks fight hard to keep those deals. For Mastercard, staying on as the “payment network” — the rails that route card purchases between merchants and banks — helps ring-fence volumes even as the issuing bank changes. Apple and Chase
8 January 2026
·····
B2PRIME plugs into TradingView, lands ‘platinum’ badge as B2TRADER trading goes chart-side

B2PRIME plugs into TradingView, lands ‘platinum’ badge as B2TRADER trading goes chart-side

LIMASSOL, Cyprus, Jan 8, 2026, 17:00 (GMT+2) B2PRIME Group said on Thursday it has integrated its B2TRADER execution platform with TradingView, letting clients place trades directly from TradingView charts. The company said TradingView has recognised it as a Platinum Partner. TradingView The timing is not random. Charting tools are being pulled deeper into execution, with brokers and institutional platforms trying to keep traders inside a single screen from analysis to order entry. Finance Magnates said TradingView integrations are expanding as platforms compete on workflow and access. Finance Magnates B2PRIME is pitching reach as much as tech. The firm said TradingView
8 January 2026
SoFi stock slips again as share-sale overhang hangs on; Jan. 30 earnings next

SoFi stock slips again as share-sale overhang hangs on; Jan. 30 earnings next

NEW YORK, Jan 7, 2026, 11:26 (EST) — Regular session SoFi Technologies shares were down about 1.4% at $26.61 by 11:26 a.m. EST on Wednesday, extending recent weakness as investors absorbed fresh details on stock sold into the market. A regulatory filing showed the underwriters of SoFi’s December share sale exercised their option to buy additional stock, and the company completed that extra issuance on Jan. 5. The “greenshoe” option — a standard clause that lets banks buy more shares — pushed total shares sold in the offering to 57,754,660 at $27.50 each, with Goldman Sachs, BofA Securities, Citigroup, Deutsche
7 January 2026
···
Nu Holdings stock dips as Nubank cools off from a 52-week high with U.S. jobs report ahead

Nu Holdings stock dips as Nubank cools off from a 52-week high with U.S. jobs report ahead

New York, January 7, 2026, 09:50 EST — Regular session Nu Holdings Ltd shares slipped about 2.2% to $17.46 in early New York trade on Wednesday, backing away from recent highs after a strong start to the year. The pullback comes with the stock still near its 52-week high — the best level in the past year — after a two-session sprint that briefly took it above $18. Macro data is driving the mood. U.S. private payrolls rose by 41,000 in December, missing forecasts for a 47,000 gain, ADP’s report showed on Wednesday, a day before traders shift attention to
7 January 2026
···
Barclays shares in focus as bank makes first stablecoin bet with Ubyx stake

Barclays shares in focus as bank makes first stablecoin bet with Ubyx stake

London, January 7, 2026, 07:51 GMT — Premarket Barclays (BARC.L) shares were set for focus ahead of the London open on Wednesday after the bank said it had bought a stake in U.S. stablecoin-settlement firm Ubyx, its first investment in a stablecoin-related company. Barclays declined to disclose the size of the investment; Ubyx runs a clearing system for stablecoins, digital tokens designed to track mainstream currencies, and Barclays was one of 10 banks including Goldman Sachs and UBS that said in October it was exploring a stablecoin pegged to G7 currencies. The stock ended Tuesday up 0.36% at 488.40 pence,
7 January 2026
·
BILL stock drops 7% to start 2026 as rate jitters hit fintech; KBW lifts target

BILL stock drops 7% to start 2026 as rate jitters hit fintech; KBW lifts target

NEW YORK, January 3, 2026, 20:13 ET — Market closed Shares of BILL Holdings, Inc. fell 7.3% on Friday to $50.56, a sharp drop on the first U.S. trading session of 2026. The decline came as investors leaned toward value stocks and away from growth names while U.S. Treasury yields moved higher. The Dow and S&P 500 ended up on the day, while the Nasdaq dipped, according to Reuters data. Reuters That matters for BILL because the fintech is often priced like a growth software company, which can make it more sensitive to shifts in rate expectations early in the
4 January 2026
···
PayPal stock slips to start 2026 as CEO leans into AI payments — what traders watch next

PayPal stock slips to start 2026 as CEO leans into AI payments — what traders watch next

NEW YORK, Jan 3, 2026, 16:19 ET — Market closed PayPal Holdings Inc shares (PYPL) ended the first trading session of 2026 lower, closing down about 0.4% at $58.14 on Friday. The stock finished 24 cents below its Dec. 31 close of $58.38, according to the company’s historical quote. The move left PayPal trading near the lower end of its recent range, keeping focus on how quickly management can reignite growth. CEO Alex Chriss told The Times he wants to push harder in the UK, including plans for PayPal-branded debit and credit cards and a loyalty programme called PayPal+. Chriss
3 January 2026
···
Coinbase stock rises after Brian Armstrong maps 2026 ‘everything exchange’ push

Coinbase stock rises after Brian Armstrong maps 2026 ‘everything exchange’ push

New York, Jan 3, 2026, 11:02 ET — Market closed Coinbase Global (COIN.O) shares rose 4.6% to $236.53 in Friday’s session after CEO Brian Armstrong laid out a 2026 plan to build what he called an “everything exchange” that stretches beyond cryptocurrencies. Decrypt The update matters because Coinbase’s results often track crypto market activity, which can swing sharply with prices and risk appetite. Investors have been looking for signs the company can add steadier growth lines, especially in payments and regulated products. It also lands as U.S. lawmakers weigh new rules for digital assets and after Washington set a federal
3 January 2026
···
Paymentus stock tumbles nearly 10% as fintech slides; oversold RSI flashes for PAY

Paymentus stock tumbles nearly 10% as fintech slides; oversold RSI flashes for PAY

NEW YORK, Jan 2, 2026, 2:07 PM ET — Regular session Paymentus Holdings, Inc. shares were down 9.7% at $28.53 in afternoon trading on Friday, after touching a session low of $28.53. The stock opened at $31.43, hit an intraday high of $31.63 and has traded about 703,000 shares, compared with a prior close of $31.59. The slide matters because Paymentus, a bill-payment software provider, has traded like a sentiment gauge for investors’ appetite for growth-oriented payments names. A near-double-digit move in a single session can force portfolio managers and short-term traders to reassess positioning quickly. The drop also lands
2 January 2026
··
SoFi stock price today: SOFI slips in premarket as rate-cut bets set the tone for fintechs

SoFi stock price today: SOFI slips in premarket as rate-cut bets set the tone for fintechs

NEW YORK, January 2, 2026, 05:03 ET — Premarket SoFi Technologies (SOFI) shares fell 1.4% to $26.18 in premarket trading on Friday, after closing at $26.56 in the prior session. The move comes as investors return for the first U.S. session of 2026 with risk appetite still holding up, after Reuters reported S&P 500 futures up 0.6% and Nasdaq futures up 1% in early moves. Reuters Rate expectations are the main near-term driver for the group. The Federal Reserve cut rates by a total 175 basis points in 2024 and 2025, and investors are watching whether cooling labor data keeps
2 January 2026
···
Chime stock slides nearly 4% in year-end trade as fintechs wobble

Chime stock slides nearly 4% in year-end trade as fintechs wobble

NEW YORK, December 31, 2025, 13:38 ET — Regular session Chime Financial (CHYM.O) shares fell about 3.9% to $25.30 on Wednesday, extending a pullback in the consumer fintech stock on the last trading day of 2025. The shares traded between $25.30 and $26.32 after opening at $26.29. The late-December tape is often noisy. Trading volumes can thin out around holidays, and that can amplify swings as investors rebalance books into year-end. That matters for Chime because newer, growth-leaning fintech listings tend to react quickly when investors rotate between riskier names and defensive corners of the market. Rate expectations also loom
31 December 2025
····
Nu Holdings (NU) stock ticks up in premarket as Nubank heads into a key earnings window

Nu Holdings (NU) stock ticks up in premarket as Nubank heads into a key earnings window

NEW YORK, December 31, 2025, 08:12 ET — Premarket Shares of Nu Holdings Ltd were up 0.7% at $17.01 in premarket trading on Wednesday, after finishing Tuesday at $16.88, up 1.3%. Yahoo Finance The early move matters because Nu has become a widely held proxy for high-growth Latin American consumer finance, and year-end liquidity can exaggerate price swings even on routine positioning. Zacks Investment Research said investors are turning attention to Nu’s next quarterly report, forecasting earnings per share of $0.18 on revenue of $4.56 billion; for the full year, it projects EPS of $0.59 and revenue of $15.65 billion.
31 December 2025
····
1 2 3 4 5 6 … 15

Stock Market Today

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

7 February 2026
New York, February 7, 2026, 05:48 EST — Market closed Pfizer Inc (PFE) shares ended Friday up 2.8% at $27.22, after trading between $26.52 and $27.37. About 50.7 million shares changed hands. (Yahoo Finance) The stock’s late-week lift comes with a key regulatory clock running: the FDA granted priority review for Pfizer’s supplemental filing to broaden use of its hemophilia drug Hympavzi, with a target decision deadline in the second quarter. Priority review shortens the agency’s standard review timeline by four months. “There is a significant medical need for younger patients with hemophilia and for those who have developed inhibitors,”
Go toTop